Page 164 - Read Online
P. 164

Page 6 of 7                                                    Strokova et al. Vessel Plus 2019;3:16  I  http://dx.doi.org/10.20517/2574-1209.2019.08

               Availability of data and materials
               Authors confirm that the data were strictly obtained from medical records according to the privacy policy
               and ethics code of our institute.

               Financial support and sponsorship
               Research work carried out at the expense of subsidies for public tasks in the framework of the Program of
               Basic Research of state academies of science for 2013-2020 (0529-2016-0007; 0529-2018-0113).

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               The study received an approval from the Local Ethic Committee (0529-2016-0007), as it was conducted
               as a part of the State Program of Basic Research. All procedures were done with accordance to GCP
               standards and Informed consents from parents or official representatives were received prior to any research
               procedures.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2019.


               REFERENCES
               1.   Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol 2007;13:2541-53.
               2.   Bhattacharya K. Investigation and management of the hepatic glycogen storage diseases. Transl Pediatr 2015;4:240-8.
               3.   Moses SW, Wanderman KL, Myroz A, Frydman M. Cardiac involvement in glycogen storage disease type III. Eur J Pediatr
                   1989;148:764-6.
               4.   Tada H, Kurita T, Ohe T, Shimomura K, Ishihara T, et al. Glycogen storage disease type III associated with ventricular tachycardia. Am
                   Heart J 1995;130:911-2.
               5.   Humbert M, Labrune PH, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr
                   2002;161:S93-6.
               6.   Humbert M, Labrune P, Sitbon O, Le Gall C, Callebert J, et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the
                   serotonin hypothesis. Eur Respir J 2002;20:59-65.
               7.   Derks TG, van Rijn M. Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future
                   directions. J Inherit Metab Dis 2015;38:537-43.
               8.   Rake JP, Visser G, Labrune P, Leonard P, Ullrich K, et al. Glycogen storage disease type I: diagnosis, management, clinical course and
                   outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002;161:S20-S34.
               9.   Greenea HL, Swift LL, Knapp HR. Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. J
                   Pediatr 1991;119:398-403.
               10.  Fernandes J, Alaupovic P, Wit JM. Gastric drip feeding in patients with glycogen storage disease type I: its effects on growth and plasma
                   lipids and apolipoproteins. Pediatr Res 1989;25:327-31.
               11.  Bandsma RH, Smit GP, Kuipers F. Disturbed lipid metabolism in glycogen storage disease type 1. Eur J Pediatr 2002;161:S65-9.
               12.  Bandsma RH, Prinsen BH, van Der Velden Mde S, Rake JP, Boer T, et al. Increased de novo lipogenesis and delayed conversion of
                   large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res
                   2008;63:702-7.
               13.  Sever S, Weinstein DA, Wolfsdorf J, Gedik R, Schaefer EJ. Glycogen storage disease type 1a: linkage of glucose, glycogen, lactic acid,
                   triglyceride, and uric acid metabolism. J Clin Lipidol 2012;6:596-600.
               14.  Carvalho PM, Silva NJ, Dias PG. Glycogen storage disease type 1a - a secondary cause for hyperlipidemia: report of five cases. J
                   Diabetes Metab Disord 2013;12:25.
               15.  Bernier AV, Sentner CP, Correia CE, Theriaque DW, Shuster JJ, et al. Hyperlipidemia in glycogen storage disease type III: effect of age
                   and metabolic control. J Inherit Metab Dis 2008;31:729-32.
               16.  Zhang PY, Xu X, Li XC. Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci
                   2014;18:3091-6.
               17.  Wittensteina B, Kleina M, Finckha B, Ullrich K, Kohlschütter A. Plasma antioxidants in pediatric patients with glycogen storage
                   disease, diabetes mellitus, and hypercholesterolemia. Free Radic Biol Med 2002;33:103-10.
               18.  Bernier AV, Correia CE, Haller MJ, Theriaque DW, Shuster JJ, et al. Vascular dysfunction in glycogen storage disease type I. J Pediatr
                   2009;154:588-91.
   159   160   161   162   163   164   165   166   167   168   169